Carlos Martin MD, PhD. Is Professor of Microbiology at the Faculty of Medicine at University of Zaragoza, Servicio de Microbiología, Hospital Miguel Servet. He is member of the Advisory Committee of Tuberculosis Vaccine Initiative (TBVI), with more than 30 years of experience in mycobacterial genetics and molecular epidemiology of TB. He and his team aim to develop novel tuberculosis vaccines and vaccination strategies to improve protection against pulmonary TB. Carlos Martin team designed and constructed MTBVAC, the first attenuated live M. tuberculosis vaccine in clinical trials, in collaboration with Professor Brigitte Gicquel team of Institut Pasteur in Paris.
From the Microbioology School of Professor Gomez-Lus, focused his studies in the mechanisms of resistance in bacteria. Dr. Martin came to the University of Zaragoza from Pasteur Institute in Paris, where he worked as permanent researcher in the Unité de Génie Microbiologique (Professor Julian Davies) and under the direction of Brigitte Gicquel specializing in Bacterial Genetics and Molecular Biology of Mycobacteria. Prior at Pasteur, he studies the mechanisms of resistance, transposition and plasmids in bacteria in the Department of Biochemistry and Molecular Biology, University of Cantabria under the Direction of Juanma García-Lobo and Fernando de la Cruz.
Carlos Martin has published more than one hundred international publication in tuberculosis cited more than 7.000 times in the last years. Dr. Martin's research has been continuously funded by National and European Union Research Programs in tuberculosis research since 1992. Carlos Martin Team is part of CIBERES, a research network on respiratory diseases of the Spanish Ministry of Health (Instituto de Salud Carlos III). He currently works in collaborative tuberculosis research projects together with research groups of Europe and Latin America.
Carlos Martin is co-inventor of several patents on "tuberculosis vaccine" owned by the University of Zaragoza, which, are exclusive licensed to Biofabri as industrial and clinical developer partner.
Some Relevant Publications:
1. Nature Communications 2017 "Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis" Aguilo et al 8, 16085.
2. Expert Review of Vaccines 2017 "MTBVAC from discovery to clinical trials in tuberculosis-endemic countries." Marinova et al 16, 6, 565–576.
3. Tuberculosis 2016 "MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice". 96:71–74.
4.- Journal of Infectious Diseases 2016 "Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism". Aguilo et al 1;213(5):831-9.
5.- Lancet Respiratory Medicine 2015 “First Human Immunization with A Live-Attenuated Mycobacterium tuberculosis: a randomized, double-blind, controlled phase I trial.” Spertini et al 3(12):953-62.
6. Vaccine 2013. "Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials". Arbues et al 1;31(42):4867-73.
7. Vaccine 2006 "The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs". Martín et al 24: 3408-19
8. Molecular Microbiology 2001 "An essential role for phoP in Mycobacterium tuberculosis virulence". Pérez et al 41: 179-87.
9. Journal of Clinical Microbiology 1993 "Strain identification of Mycobacterium-tuberculosis by DNA fingerprinting - recommendations for a standardized methodology "– Van Embden et al. 31 406-9.
10. Nature 1990. "Transposition of an antibiotic-resistance element in mycobacteria". Martín et al. 345:739-43.